Table 1

Arguments for therapeutic drug monitoring of a tumour necrosis factor inhibitor in rheumatic diseases and requirements

Pharmacokinetic interindividual variabilityValid assay for drug concentration measurement and anti-drug antibody detection
Dose–concentration relationshipAlgorithm based on clinical and biological assessment
Risk of adverse events, outside the target concentration range* Personalised dosing-schedule modelling tool, to achieve the target concentration and response
  • *Immunogenicity with low concentrations and infection with high concentrations.